Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual MeetingBusiness Wire • 10/31/24
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary CholangitisBusiness Wire • 10/10/24
Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/06/24
Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • 08/07/24
Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024Business Wire • 07/31/24
Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?Zacks Investment Research • 07/29/24
Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic AcquisitionSeeking Alpha • 07/17/24
Mirum Pharmaceuticals' LIVMARLI Approved in the European Union for Patients with PFICBusiness Wire • 07/08/24
Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTXBusiness Wire • 06/28/24
Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?Zacks Investment Research • 06/18/24
Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage StudiesBenzinga • 06/17/24
Mirum's Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC StudiesBusiness Wire • 06/17/24
Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024Business Wire • 06/16/24
Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?Zacks Investment Research • 06/07/24
Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceBusiness Wire • 06/05/24
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and OlderBusiness Wire • 05/31/24